Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) have received an average rating of "Moderate Buy" from the eight research firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $57.33.

A number of equities research analysts have recently issued reports on the stock. Bank of America lowered their price target on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a report on Tuesday. Scotiabank lowered their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a report on Friday, May 2nd. Finally, Wall Street Zen downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th.

Insider Activity

In other Agios Pharmaceuticals news, insider James William Burns sold 2,799 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $93,878.46. Following the transaction, the insider directly owned 28,650 shares of the company's stock, valued at approximately $960,921. This trade represents a 8.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Brian Goff sold 18,700 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $627,198.00. Following the transaction, the chief executive officer directly owned 105,401 shares in the company, valued at $3,535,149.54. This trade represents a 15.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 46,363 shares of company stock valued at $1,619,654. Insiders own 4.30% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new position in shares of Agios Pharmaceuticals in the fourth quarter worth approximately $39,000. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the first quarter worth approximately $40,000. CWM LLC grew its holdings in shares of Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 996 shares during the last quarter. Sterling Capital Management LLC grew its holdings in shares of Agios Pharmaceuticals by 818.0% in the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after purchasing an additional 1,587 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Agios Pharmaceuticals by 16.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 320 shares during the last quarter.

Agios Pharmaceuticals Stock Up 0.9%

AGIO traded up $0.35 during trading on Thursday, hitting $40.00. 529,138 shares of the company traded hands, compared to its average volume of 668,393. The firm has a market cap of $2.32 billion, a P/E ratio of 3.56 and a beta of 0.73. Agios Pharmaceuticals has a one year low of $23.42 and a one year high of $62.58. The stock's fifty day moving average is $34.77 and its 200 day moving average is $32.46.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. The firm had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.86 million. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. On average, equities research analysts forecast that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.